Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $1.14 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.67, representing an earnings surprise of -70.15% [1] - The company posted revenues of $0.2 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 23.57%, and a significant decline from $1.04 million in the same quarter last year [2] - The stock has underperformed significantly, losing about 74.1% since the beginning of the year, compared to a 14.6% gain in the S&P 500 [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters, but the recent report indicates a negative trend in earnings expectations [2][6] - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $0.26 million, and for the current fiscal year, it is -$4.80 on revenues of $3.19 million [7] Industry Context - Clearside Biomedical operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 36% of over 250 Zacks industries [8] - The performance of the stock may be influenced by the overall outlook of the industry, as historically, the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]